{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:56:00Z","timestamp":1792119360057,"version":"4.4.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s11523-024-01059-8","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T17:01:47Z","timestamp":1715274107000},"page":"473-480","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Futibatinib: A Review in Locally Advanced and Metastatic Cholangiocarcinoma"],"prefix":"10.1007","volume":"19","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"issue":"2","key":"1059_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127\u201340.","journal-title":"Ann Oncol"},{"key":"1059_CR2","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in oncology: biliary tract cancers. Version 3.2023 \u2013 November 8, 2023. 2023. https:\/\/www.nccn.org\/. Accessed 19 Feb 2024."},{"issue":"1","key":"1059_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/gutjnl-2023-330029","volume":"73","author":"SM Rushbrook","year":"2023","unstructured":"Rushbrook SM, Kendall TJ, Zen Y, et al. British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma. Gut. 2023;73(1):16\u201346.","journal-title":"Gut"},{"issue":"9","key":"1059_CR4","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557\u201388.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1059_CR5","unstructured":"Mayo Clinic. Cholangiocarcinoma (bile duct cancer). 2023. https:\/\/www.mayoclinic.org\/diseases-conditions\/cholangiocarcinoma\/symptoms-causes\/syc-20352408. Accessed 19 Feb 2024."},{"issue":"11","key":"1059_CR6","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1093\/oncolo\/oyad149","volume":"28","author":"M Javle","year":"2023","unstructured":"Javle M, King G, Spencer K, et al. Futibatinib, an irreversible FGFR1-4 inhibitor for the treatment of FGFR-aberrant tumors. Oncologist. 2023;28(11):928\u201343.","journal-title":"Oncologist"},{"issue":"9","key":"1059_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e19541","volume":"9","author":"D Wekking","year":"2023","unstructured":"Wekking D, Pretta A, Martella S, et al. Fibroblast growth factor receptors as targets for anticancer therapy in cholangiocarcinomas and urothelial carcinomas. Heliyon. 2023;9(9): e19541.","journal-title":"Heliyon."},{"key":"1059_CR8","unstructured":"Taiho Pharma Netherlands B.V. Lytgobi (futibatinib) 4 mg film-coated tablets: EU summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lytgobi. Accessed 19 Feb 2024."},{"key":"1059_CR9","unstructured":"Taiho Oncology Inc. LYTGOBI\u00ae (futibatinib) tablets, for oral use: US prescribing information. 2022. https:\/\/www.fda.gov\/. Accessed 19 Feb 2024."},{"key":"1059_CR10","unstructured":"Taiho Pharmaceutical Co. Ltd. LYTGOBI\u00ae (futibatinib) 4 mg tablets: Japanese prescribing information. 2023. https:\/\/www.pmda.go.jp\/. Accessed 19 Feb 2024."},{"issue":"4","key":"1059_CR11","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/cmdc.201800719","volume":"14","author":"M Kalyukina","year":"2019","unstructured":"Kalyukina M, Yosaatmadja Y, Middleditch MJ, et al. TAS-120 cancer target binding: defining reactivity and revealing the first fibroblast growth factor receptor 1 (FGFR1) irreversible structure. ChemMedChem. 2019;14(4):494\u2013500.","journal-title":"ChemMedChem"},{"issue":"22","key":"1059_CR12","doi-asserted-by":"publisher","first-page":"4986","DOI":"10.1158\/0008-5472.CAN-19-2568","volume":"80","author":"H Sootome","year":"2020","unstructured":"Sootome H, Fujita H, Ito K, et al. Futibatinib is a novel irreversible FGFR 1\u20134 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. Cancer Res. 2020;80(22):4986\u201397.","journal-title":"Cancer Res"},{"issue":"18","key":"1059_CR13","doi-asserted-by":"publisher","first-page":"4446","DOI":"10.3390\/cancers15184446","volume":"15","author":"M Valery","year":"2023","unstructured":"Valery M, Vasseur D, Fachinetti F, et al. Targetable molecular alterations in the treatment of biliary tract cancers: an overview of the available treatments. Cancers (Basel). 2023;15(18):4446.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"1059_CR14","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","volume":"9","author":"L Goyal","year":"2019","unstructured":"Goyal L, Shi L, Liu LY, et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov. 2019;9(8):1064\u201379.","journal-title":"Cancer Discov"},{"issue":"10","key":"1059_CR15","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/2159-8290.CD-20-1669","volume":"11","author":"JM Cleary","year":"2021","unstructured":"Cleary JM, Raghavan S, Wu Q, et al. FGFR2 extracellular domain in-frame deletions are therapeutically targetable genomic alterations that function as oncogenic drivers in cholangiocarcinoma. Cancer Discov. 2021;11(10):2488\u2013505.","journal-title":"Cancer Discov"},{"issue":"10","key":"1059_CR16","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.annonc.2020.06.018","volume":"31","author":"R Bahleda","year":"2020","unstructured":"Bahleda R, Meric-Bernstam F, Goyal L, et al. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors. Ann Oncol. 2020;31(10):1405\u201312.","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"1059_CR17","doi-asserted-by":"publisher","first-page":"S378","DOI":"10.1016\/j.annonc.2021.08.331","volume":"32","author":"A Hollebecque","year":"2021","unstructured":"Hollebecque A, Bridgewater JA, Meric-Bernstam F, et al. Assessment of futibatinib exposure-response (E-R) relationships in patients with advanced solid tumors, including cholangiocarcinoma (CCA) [abstract no. 52P]. Ann Oncol. 2021;32(Suppl 5):S378\u20139.","journal-title":"Ann Oncol"},{"issue":"3","key":"1059_CR18","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/cpdd.1195","volume":"12","author":"I Yamamiya","year":"2023","unstructured":"Yamamiya I, Lester R, Sonnichsen D, et al. Effect of futibatinib on cardiac repolarization: results of a randomized, controlled, double-blind, QT\/QTc, phase 1 study in healthy subjects. Clin Pharmacol Drug Dev. 2023;12(3):304\u201313.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"3","key":"1059_CR19","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/cpdd.1196","volume":"12","author":"I Yamamiya","year":"2023","unstructured":"Yamamiya I, Hunt A, Yamashita F, et al. Evaluation of potential food effects and drug interactions with lansoprazole in healthy adult volunteers receiving futibatinib. Clin Pharmacol Drug Dev. 2023;12(3):294\u2013303.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"10","key":"1059_CR20","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/cpdd.1259","volume":"12","author":"I Yamamiya","year":"2023","unstructured":"Yamamiya I, Hunt A, Takenaka T, et al. Evaluation of the cytochrome P450 3A and p-glycoprotein drug-drug interaction potential of futibatinib. Clin Pharmacol Drug Dev. 2023;12(10):966\u201378.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"9","key":"1059_CR21","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1111\/cts.13585","volume":"16","author":"L Gao","year":"2023","unstructured":"Gao L, Yamamiya I, Pinti M, et al. A phase I, open-label, single-dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib. Clin Transl Sci. 2023;16(9):1713\u201324.","journal-title":"Clin Transl Sci"},{"issue":"2","key":"1059_CR22","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/cas.15486","volume":"114","author":"T Doi","year":"2023","unstructured":"Doi T, Shitara K, Kojima T, et al. Phase I study of the irreversible fibroblast growth factor receptor 1\u20134 inhibitor futibatinib in Japanese patients with advanced solid tumors. Cancer Sci. 2023;114(2):574\u201385.","journal-title":"Cancer Sci"},{"issue":"3","key":"1059_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388(3):228\u201339.","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"1059_CR24","doi-asserted-by":"publisher","first-page":"S261","DOI":"10.1016\/j.annonc.2020.08.032","volume":"31","author":"J Bridgewater","year":"2020","unstructured":"Bridgewater J, Meric-Bernstam F, Hollebecque A, et al. Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions\/other rearrangements: subgroup analyses of a phase II study (FOENIX-CCA2) [abstract no. 54P]. Ann Oncol. 2020;31(Suppl 4):S261\u20132.","journal-title":"Ann Oncol"},{"key":"1059_CR25","unstructured":"European Medicines Agency. Lytgobi (futibatinib): EU assessment report. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lytgobi. Accessed 19 Feb 2024."},{"key":"1059_CR26","unstructured":"US Food and Drug Administration. Futibatinib (Lytgobi): multi\u2010disciplinary review and evaluation. 2022. https:\/\/www.fda.gov\/. Accessed 19 Feb 2024."},{"key":"1059_CR27","doi-asserted-by":"crossref","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, et al. Updated results of the FOENIX-CCA2 trial: efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions\/rearrangements [abstract no. 4009]. J Clin Oncol. 2022;40(16 Suppl).","DOI":"10.1200\/JCO.2022.40.16_suppl.4009"},{"issue":"4 Suppl","key":"1059_CR28","first-page":"400","volume":"40","author":"MJ Borad","year":"2022","unstructured":"Borad MJ, Paine A, Wacheck V, et al. Indirect treatment comparison of futibatinib with chemotherapy and pemigatinib in cholangiocarcinoma with FGFR2 fusions\/rearrangements [abstract no. 440]. J Clin Oncol. 2022;40(4 Suppl):400.","journal-title":"J Clin Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01059-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-024-01059-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01059-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T13:22:09Z","timestamp":1716384129000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-024-01059-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1059"],"URL":"https:\/\/doi.org\/10.1007\/s11523-024-01059-8","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"27 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sheridan M. Hoy is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}